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Human tissue kallikreins are a family of 15 trypsin or chymotrypsin-like secreted serine proteases (hK1–hK15). hK5,
hK6, hK7, hK8, and hK13 have been identiﬁed in the stratum corneum (SC), stratum granulosum, and skin ap-
pendages. It has been reported that hK5 and hK7 degrade desmosomes/corneodesmosomes, suggesting that
kallikreins are responsible for desquamation. We report the quantiﬁcation of hK5, hK6, hK7, hK8, hK10, hK11, hK13,
and hK14 in the SC by ELISA and their variation among age groups. The total SC trypsin and chymotrypsin-like
activities were also measured. The amount of hK7, hK8, and hK11 (ng per mg dry weight) were high, and varied
from 6 to 14, hK5 (2.0–4.0) was present at intermediate levels, and hK10 (0.65–1.0), hK14 (0.1–0.3), hK6 (0.1–0.3), and
hK13 (0.02–0.1) were present at lower levels. hK6 and hK14 were significantly lower in females between 20 and 59 y.
hK5, hK7, hK10, hK11, and hK14 were not significantly different across the age groups. hK8 was lowest at extremes
of age (highest at 30–39 y), hK6 was lower at 430 y, and hK13 was lower at 420 y. Overall trypsin-like activity did
not differ across age groups but was higher in subjectso11 y. Overall chymotrypsin-like activity was not related to
age. In conclusion, we found multiple kallikreins in the SC and suggest that these enzymes may be responsible for
desquamation through an enzymatic cascade pathway.
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Numerous studies during the last 30 y have demonstrated
that the stratum corneum (SC) is structurally and biochem-
ically diverse and plays key roles in skin barrier function and
aging. The SC structure, the SC lipids, the number of SC
layers, and the transepidermal water loss have been
shown to be important in these processes (Harding, 2004;
Marks, 2004). In addition, the desquamation process has
also been recognized to be important for the maintenance
of skin barrier function. The proliferation rate of keratin-
ocytes and their transformation into corneocytes is
matched by the shedding of old corneocytes at the SC
regardless of age (Ya-Xian et al, 1999; Harding et al,
2000), with a turnover time through the SC estimated to
be 14 d in normal skin (Halprin, 1972; Pierard et al, 2000).
The SC appears to desquamate at a fixed rate that is
uninfluenced by external forces (Kligman, 1964). The des-
quamation of corneocytes requires both ‘‘trypsin-like’’ and
‘‘chymotrypsin-like’’ serine protease activities (Suzuki et al,
1996) for desmosome and/or corneodesmosome degrada-
tion (Chapman and Walsh, 1990). It is likely that there is a
regulatory system maintaining serine protease activity in
order to sustain a steady skin barrier function.
The human tissue kallikrein (KLK) gene family localizes as
a cluster to chromosome 19q13.4 and encodes 15 secre-
tory serine proteases (hK1–hK15) (Yousef and Diamandis,
2001) that have been suggested to function as an enzymatic
cascade pathway in many tissues (Yousef and Diamandis,
2002). In the case of skin tissue, several kallikreins, includ-
ing hK5 (previously known as SC trypsin-like enzyme,
SCTE; Brattsand and Egelrud, 1999; Yousef and Diamandis,
1999), hK7 (previously known as SC chymotrypsin-like en-
zyme, SCCE; Hansson et al, 1994), as well as hK6, hK8,
and hK13 (Komatsu et al, 2005), have been identified
immunohistochemically in the SC, the stratum granulosum,
and the skin appendages, and are predicted to be secretory
serine proteases involved in skin desquamation. Functional
studies have shown that hK7 cleaves corneodesmosin and
desmocollin 1 (Caubet et al, 2004), and that the pro-forms of
hK7 and hK14 are activated by hK5. Activation of pro-hK5 is
either autocatalytic or is mediated by hK14 (Brattsand et al,
2005). hK5 also degrades corneodesmosin (Simon et al,
2001).
hK5, hK7, and hK8 have been found to be transported
from the trans-Golgi network within lamellar granules, and
the granules are released from the apical surface of the
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most-superficial granular cells (Ishida-Yamamoto et al,
2004, 2005). In addition, previous in situ hybridization
studies have identified KLK1, KLK4, KLK9, KLK10, KLK11,
and KLK14 as additional serine protease genes that
are candidate players in desquamation (Komatsu et al,
2003).
But it has not as yet been determined if these kallikreins
are detectable at the protein level in the SC, if their con-
centration changes with aging, and to what extent each
kallikrein contributes to the total SC serine protease
activity. Here, we report quantification of hK5, hK6, hK7,
hK8, hK10, hK13, and hK14 in the SC of individuals of
various ages by ELISA assays and correlate these amounts
with total SC trypsin- and chymotrypsin-like enzymatic
activities.
Results
Kallikrein levels in the SC among age groups We used
in-house developed immunofluorometric assays (ELISA) to
quantitatively determine the amounts of hK5, hK6, hK7,
hK8, hK10, hK11, hK13, and hK14 in normal SC extracts. In
Table I, kallikrein concentrations are reported in groups
stratified by age (per decade from age 20 to 59 y) and fur-
ther subdivided by gender. Figure 1 displays the kallikrein
concentrations among age groups, in which male and fe-
male values are combined, and includes subjects less than
11 y and older than 70 y. The same specimens were also
analyzed for hK4 using a method described in Table II, but
as 60% of the samples had undetectable hK4 concentra-
tion, this kallikrein was excluded from further analysis.
Table I. Kallikrein quantiﬁcation in the stratum corneum among age groupsa
hK Sex
20s:
mean  SD
M (n¼15)
F (n¼15)
(%)
30s:
mean  SD
M (n¼15)
F (n¼ 15)
(%)
40s:
mean  SD
M (n¼ 15)
F (n¼ 15)
(%)
50s:
mean  SD
M (n¼ 15)
F (n¼15)
(%)
Chymotrypsin-like hK
hK7 M 13.7  8.0 11.1  6.4 12.9  11.7 7.4  7.8
F 11.3  12.3 13.8  12.6 11.7  6.6 10.5  7.2
Average 12.5 12.4 12.3 8.9
Trypsin-like hK
hK8 M 8.1  2.9 42.8 9.0  3.9 41.0 8.4  4.4 37.4 7.6  4.6 39.0 
F 9.8  3.3 42.8 14.4  4.6 53.7 11.6  3.5 45.8 6.1  1.6 32.9
hK11 M 7.5  3.1 39.8 9.0  4.5 41.1 8.8  3.5 39.4 8.5  6.4 44.0
F 9.2  6.7 40.2 8.5  4.1 31.6 10.1  3.8 39.9 8.3  4.4 44.9
hK5 M 1.9  0.85 10.1 2.8  1.0 12.8 3.8  3.5 16.8 2.0  1.8 10.3
F 2.4  0.98 10.5 2.9  1.5 10.7 2.6  1.2 10.1 3.2  1.7 17.5
hK10 M 0.70  0.47 3.7 0.69  0.39 3.2 0.98  0.58 4.4 0.93  0.80 4.8
F 0.94  0.34 4.1 0.68  0.35 2.5 0.70  0.42 2.7 0.66  0.32 3.6
hK14 M 0.31  0.20 1.6 0.23  0.21 1.0 0.24  0.15 1.1 0.18  0.16 0.9 
F 0.22  0.14 1.0 0.18  0.15 0.7 0.22  0.086 0.8 0.12  0.083 0.6
hK6 M 0.31  0.054 1.6 0.14  0.075 0.6 0.16  0.096 0.7 0.13  0.088 0.7 
F 0.26  0.048 1.1 0.10  0.032 0.4 0.11  0.058 0.4 0.087  0.048 0.5
hK13 M 0.033  0.021 0.2 0.054  0.044 0.2 0.033  0.046 0.1 0.045  0.038 0.2
F 0.063  0.040 0.3 0.12  0.072 0.4 0.046  0.054 0.2 0.018  0.013 0.1
Total of trypsin-like hK
M 18.9  5.4 21.9  8.0 22.4  9.9 19.4  11.2
F 22.8  11.4 26.8  7.2 25.4  6.8 18.5  5.8
Average 20.9 24.3 23.9 18.9
aThe values indicate the mean  SD (ng per mg dry weight). The percentage represents the concentration of each trypsin-like kallikrein compared with
the total concentration of all trypsin-like kallikreins.
Two-way ANOVA showed significant differences among age groups for hK8 (po0.05) and between genders for hK6 and hK14 (po0.05). More
details are described in ‘‘Results.’’
M, male; F, female; n, number of samples.
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Figure 1
Kallikrein quantification in the stratum corneum among age groups. The Y-axes represent mean concentrations of each kallikrein, and the error
bars indicate  SD, for each age group, combining males and females. Lines and () indicate significant differences (po0.05) between the specified
age groups. For discussion, see text.
Table II. Experimental conditions for the immunoﬂuorometric assaysa
hK4 hK5 hK6 hK7 hK8 hK10 hK11 hK13 hK14
Sample dilution
(fold)
None 5 None 5 5 None 5 None None
Capture Ab Mono Mono Mono Mono Mono Mono Mono Mono Mono
anti-hK detection
Ab
Poly Biot mono Biot mono Biot mono Biot mono Biot mono Poly Biot mono Poly
Dilution (fold)b 2,000 2,000 500 1,000 1,000 2,000 2,000 2,000 2,000
Secondary
detection
GARIg-
ALP
SA-ALP SA-ALP SA-ALP SA-ALP SA-ALP GARIg-ALP SA-ALP GARIg-ALP
Dilution (fold)b 3,000 20,000 20,000 20,000 20,000 20,000 3,000 20,000 3,000
Diluted in Assay
buffer
BSA buffer BSA buffer BSA buffer BSA buffer BSA buffer Assay buffer BSA buffer Assay buffer
Incubation time
(min)
45 15 15 15 15 15 45 15 45
aAb, antibody; SA, streptavidin; ALP, alkaline phosphatase; BSA, bovine serum albumin; GARIg, goat anti-rabbit Ab; mono, monoclonal; poly,
polyclonal; biot, biotinylated. All monoclonal antibodies were developed in mice and all polyclonal antibodies in rabbits. All capture antibodies were used
at amounts of 500 ng per 100 mL per well except for the hK11 assay (250 ng per well). See also cited literature for more details on these ELISA assays.
bAll stock antibodies or streptavidin solutions were 1 mg per mL.
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As the hKs have been predicted to have either chymotryp-
sin-like (hK7) or trypsin-like activity (hK5, hK6, hK8, hK10,
hK11, hK13, and hK14) (Yousef and Diamandis, 2001), they
have also been subdivided according to this classification.
In this study, ‘‘trypsin-like activity’’ refers to the activity of an
enzyme towards a Boc-Phe-Ser-Arg-AMC (FSR-) substrate.
‘‘Chymotrypsin-like activity’’ refers to the activity of an
enzyme towards a MeO-Suc-Arg-Pro-Tyr-pNA-HCl (RPY-)
substrate.
The mean concentration of the chymotrypsin-like kalli-
krein hK7 ranged from 7.5 to 14 ng per mg dry weight, but
no significant differences were observed among any of the
age groups (Table I and Fig 1a). Among trypsin-like kallik-
reins, hK8 and hK11 were abundant (mean values of 6–14
ng per mg dry weight for each) in all age and gender groups,
representing 80%–85% of the total amounts of trypsin-like
kallikreins detected (Table I). hK8 was present at lower lev-
els at the extremes of age (highest in the 30s), and the
amount of hK8 was significantly different between groups
o11 y and 30s (po0.01), and between 470 y and 20s,
30s, and 40s (po0.01 for each comparison) (Table I and
Fig 1b). In contrast, hK11 did not differ between subjects
stratified by age or gender (Table I and Fig 1c). The mean
concentrations of hK5 (2.0–4.0 ng per mg), representing
10%–17% of total trypsin-like kallikreins, and hK10 (0.65–
1.0 ng per mg), representing 2.5%–5.0% of total trypsin-like
kallikreins, did not differ significantly among age and gender
groups (Table I and Fig 1d and e). hK14 and hK6 levels in
females were significantly lower than in males in all age
groups (po0.01) (Table I), and their quantity was 0.1–0.3 ng
per mg (0.4%–1.6% of total trypsin-like kallikreins) for each.
In addition, the level of hK6 was lower at ages over 30 y
(po0.01 for each comparison) (Fig 1g). Although hK13 was
detectable in all cases, its levels were consistently very low
in all samples, and represented only 0.02–0.2 ng per mg,
corresponding to 0.1%–0.3% of total trypsin-like kallikreins
(Table I and Fig 1h). hK13 levels in subjects o11 y were
significantly higher than in other age groups (po0.01 for
each comparison) (Fig 1h).
Total SC trypsin- and chymotrypsin-like kallikrein con-
centration among age groups The overall concentrations
of chymotrypsin-like kallikreins (i.e., hK7) and trypsin-like
kallikreins (i.e., the sum of the concentrations of all other
kallikreins) are shown in Fig 2. The amount of the chymo-
trypsin-like kallikrein (hK7) did not differ significantly across
age groups (as also shown in Fig 1a). However, the total
concentration of trypsin-like kallikreins was higher in the
30s and 40s age groups compared with subjects 470 y
(po0.05). On the other hand, the total concentration of
chymotrypsin-like plus trypsin-like hK did not differ among
groups. The total concentration of trypsin-like kallikreins
was approximately 2-fold higher than the chymotrypsin-like
kallikrein.
SC trypsin-like enzymatic activity among age groups
The SC trypsin-like enzymatic activity was measured in
normal skin samples from each individual (Fig 3). When the
SC samples were boiled for 5 min, the activity was com-
pletely lost (data not shown). The activities displayed no
significant differences among the 20s to 50s age and gen-
der groups (data not shown). Figure 3a displays the activity
among age groups in which male and female values are
combined and includes subjects o11 and 470 y. Subjects
o11 y display the highest trypsin-like activity at any time
point. According to a trypsin calibration curve, the trypsin-
like activity per milligram of SC was comparable with  1
ng of trypsin (data not shown). Although the trypsin-like
activity among subjects 470 y of age was slightly lower
than any other age group, statistically significant differences
were not observed, except for subjects o11 y.
In Fig 3b, the correlation between the total concentra-
tions of trypsin-like kallikreins and the trypsin-like activities
in the samples is shown. The total concentrations of trypsin-
like kallikreins and trypsin-like activity were weakly corre-
lated (r¼0.40, po0.01). As the number of samples in the
o11 and 470 y age groups were small, and subjects
o11 y had significantly elevated trypsin-like activity (Fig 3a),
these points were excluded from the regression analysis.
SC chymotrypsin-like enzymatic activity among age
groups As shown in Fig 4, the SC chymotrypsin-like
enzymatic activity in normal skin samples was also meas-
ured in a subset of subjects (n¼6 for each age group). In
this assay, measurements were taken at 2 and 4 h. When
the SC samples were boiled for 5 min, the activity was
completely lost (data not shown). The pNA release was in-
sufficient to generate standard chymotrypsin curves. None-
theless, when the samples were categorized by age groups,
the chymotrypsin-like activity for all groups increased in a
time-dependent manner with no significant differences at
any time point (Fig 4a).
The correlation between the concentration of the chymo-
trypsin-like kallikrein (i.e., hK7) and the chymotrypsin-like
activity is shown in Fig 4b. The concentration and activity
were moderately correlated (r¼0.62, po0.01). Another
chymotrypsin substrate with phenylalanine in the P1 posi-
tion was inactive against the SC samples (data not shown).
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Differences in the total concentrations of trypsin-like and chymo-
trypsin-like kallikreins in the stratum corneum among age groups.
The solid bars and open bars indicate the concentrations of chymo-
trypsin-like kallikrein (hK7) and trypsin-like kallikreins (hK5, hK6, hK8,
hK10, hK11, hK13, and hK14) (mean  SD), respectively. The error bars
indicate the standard deviation of trypsin- or chymotrypsin-like kalli-
krein in each age group, females and males combined. Significant
differences (po0.05) between the total concentration of trypsin-like
kallikreins and of chymotrypsin-like kallikrein in the specified age
groups. Lines and significant differences (po0.05) in the total con-
centration of trypsin-like kallikreins between the specified age groups.
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Discussion
This study aimed to quantitatively measure human tissue
kallikreins, hK5, hK6, hK7, hK8, hK10, hK11, hK13, and
hK14, as well as the total trypsin-like and chymotrypsin-like
activities in the normal SC. The data were further compared
between genders and various age groups.
Despite their similarities, kallikreins were detected at
varying amounts in different organs and displayed different
types of enzymatic activity, e.g. hK3, hK7, and hK9 have
chymotrypsin-like activity, whereas the rest possess tryp-
sin-like activity (Yousef and Diamandis, 2001). KLK3 and
KLK9 mRNA have not been conclusively shown to be
expressed in the skin (Gan et al, 2000; Harvey et al, 2000;
Komatsu et al, 2003). hK7 is likely the major chymotrypsin-
like hK in the SC; this is in accord with our data showing
consistently high hK7 levels in the SC across all age groups
and a significant correlation between hK7 immunoreactivity
by ELISA and chymotrypsin-like activity in the SC (Fig 4b).
In addition, we observed strong similarities between hK7’s
activity toward the RPY substrate (Franzke et al, 1996)
and the overall SC chymotrypsin-like activity profile, which
further suggests that hK7 is largely responsible for this
activity.
Our immunofluorometric ELISA assays confirmed that at
least seven trypsin-like hK are detectable in the normal SC:
hK5, hK6, hK8, hK10, hK11, hK13, and hK14. The concen-
trations of trypsin-like kallikreins range widely; the concen-
tration difference between the least (hK13) and the most
abundant (hK8 or hK11) kallikreins is approximately 200-
fold. The total concentration of trypsin-like hK is about
2-fold greater than that of chymotrypsin-like hK. The total
concentration of trypsin-like kallikreins showed significant
differences across age groups (decreasing with age),
whereas the chymotrypsin-like kallikrein (i.e., hK7) was
present at more uniform levels (Fig 2). Therefore, the SC
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Figure 3
The stratum corneum (SC) trypsin-like enzymatic activity among age groups. The SC trypsin-like activities (mean  SD) represent released
AMC from the synthetic substrate. (a) Activity among age groups when male and female subjects are combined, plus subjects o11 and 470 y.
Significant difference (po0.05) betweeno11 and470 y age groups at 2 h and significant differences (po0.05) betweeno11 y and all the other
age groups at 3 h; (b) correlation between the total concentrations of trypsin-like kallikreins measured by ELISA and trypsin-like enzymatic activities.
Data from 20s to 50s age groups inclusive were used for the regression analysis. Although the data points are shown (triangles), theo11 and470 y
age groups were small and subjects o11 y had significantly elevated trypsin-like activity; for these reasons, these points were excluded from the
regression analysis. The equation of the regression line is y¼0.20xþ 9.0.
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trypsin-like activity may play a more significant role with
regard to skin aging than the SC chymotrypsin-like
activity.
We report for the first time that hK8 and hK11 are the
most abundant trypsin-like skin kallikreins; consistent with
the high expression of KLK11 mRNA previously detected in
skin (Komatsu et al, 2003), hK11 protein levels were rela-
tively high, regardless of age or gender. hK11 could there-
fore be an important trypsin-like kallikrein in the SC. hK8
levels were significantly different among age groups
(Fig 1b), and this variation contributes to the changes seen
with age with respect to total trypsin-like kallikrein levels.
Our results and those from another report describing that
KLK8-deficient mice showed a reduced rate of recovery of
the epidermis and corneocytes after ultraviolet B irradiation
suggest that hK8 might be involved in skin differentiation
(Kirihara et al, 2003). However, a previous RT-PCR study
amplified only KLK8 mRNA splice variants that are predict-
ed to code for non-functional hK8 (Komatsu et al, 2003).
Further work is necessary to elucidate whether the hK8 de-
tected in this study is, in fact, a functional enzyme.
hK5, another trypsin-like kallikrein, was originally identi-
fied in skin (Brattsand and Egelrud, 1999). We show here
that hK5 is the third most abundant hK in the SC, after hK8
and hK11. hK5 accounts for 10%–17% of total trypsin-like
kallikreins and is one of the major trypsin-like kallikreins in
the SC.
hK10, hK14, hK6, and hK13 were found at relatively low
levels in the SC, together totalling less than 10% of the SC
trypsin-like kallikreins. hK14 and hK6 levels were signifi-
cantly lower in females of the 20s to 50s age groups,
inclusive KLK14 (Yousef et al, 2003a), KLK6 (Yousef et al,
1999), and other kallikreins are upregulated by steroid hor-
mones (Yousef and Diamandis, 2001). Therefore, expression
of kallikreins could be steroid hormone dependent in the
SC. The amount of hK6 in subjects o11 y and in their 20s,
and hK13 in subjects o11 y suggests that these kallikreins
might be associated with SC differentiation at early ages.
Although KLK4 mRNA was detected in skin tissue (Komatsu
et al, 2003), our immunofluorometric assay did not detect
hK4 in a large proportion of specimens. Further studies are
necessary to examine hK4 presence in skin. Even though
levels of hK6, hK10, hK13, and hK14 were low in the normal
SC, these kallikreins could provide diversity to the SC serine
protease activity and could target as yet unidentified spe-
cific substrates.
The number of SC layers is known to be unaffected by
aging (Ya-Xian et al, 1999), and this study demonstrated
that the overall SC trypsin- and chymotrypsin-like activities
were largely similar in subjects in their 20s to 470 y of
age. As increases and decreases in the SC protease
activity seen in Netherton syndrome (Komatsu et al, 2002)
and ichthyosis vulgaris (Suzuki et al, 1996), respectively,
may cause aberrant desquamation, maintenance of a
stable SC serine protease activity may be essential for re-
taining a stable number of SC layers and proper skin barrier
function.
As hK7 exists in the SC as a mixture of the pro-form and
the active form (Ekholm and Egelrud, 1999), trypsin-like
kallikreins may also be present in both pro- and active
forms.
It is likely, as previously suggested (Caubet et al, 2004;
Yousef and Diamandis, 2002), that pro-forms of some
kallikreins are activated by other kallikreins, thus creating
a cascade reaction. This possibility merits further in-
vestigation.
Subjects under 11 y old always had the highest trypsin-
and chymotrypsin-like activities, whereas the total concen-
tration of trypsin- and chymotrypsin-like kallikreins was
lower than those of the 20s to 50s age groups. This implies
that younger subjects might possess a higher proportion of
hK in the active form, or their SC contains as yet uniden-
tified proteases.
Recent studies demonstrated the lamellar granular lo-
calization of hK5, hK7, and hK8, and the secretion of gran-
ules into intercellular spaces (Ishida-Yamamoto et al, 2004,
2005) and the degradation of desmosomes and/or corn-
eodesmosomes by hK5 and hK7 (Simon et al, 2001; Caubet
et al, 2004). These data strongly implicate these two kallik-
reins in desquamation. In addition, kallikreins tend to be
detected in more highly differentiated cells, i.e., the stratum
granurosum, SC, and appendages, which implies that
kallikreins might also be related to skin maturation and dif-
ferentiation (Ekholm et al, 2000, Komatsu et al, 2005). Our
study detected the kallikreins in the superficial SC. Kallik-
reins are likely present at higher concentrations in the
deeper SC, and could be present in all SC layers as reactive
proteases against external stimuli. Following our original
suggestion for kallikrein involvement in a proteolytic cas-
cade pathway (Yousef and Diamandis, 2002), others pro-
posed similar pathways in the skin for kallikreins hK5, hK7,
and hK14 (Brattsand et al, 2005). Our data suggest that this
pathway is likely more complex and involves at least eight
kallikreins (hK5, hK6, hK7, hK8, hK10, hK11, hK13, and
hK14).
In summary, we report for the first time the quantification
of numerous kallikreins in normal SC. The hK family is an
important protease group within SC, with a large diversity in
both quantity and activity. The data presented here may aid
in the better understanding of skin barrier function and ag-
ing, especially in conjunction with desquamation. It will be
of interest to quantitatively compare kallikrein levels and
activity of normal and diseased skin.
Materials and Methods
Skin samples and preparation of extracts The SC samples were
obtained from the forearm of 135 normal volunteers (15 females
and 15 males) in each of four groups with ages 20–29, 30–39, 40–
49, and 50–59 y, respectively, nine (four females and five males)
with ages less than 11 y, and six (five females and one male) with
ages over 70 y). Informed consent was obtained from all partic-
ipants and our study was conducted according to the Declaration
of Helsinki. The medical ethical committee of the Graduate School
of Medical Science, School of Medicine, Kanazawa University ap-
proved all described studies. SC was obtained by stripping using
Nichiban tape (organic solvent-stable tape with organic solvent-
soluble adhesive, Nichiban, Tokyo, Japan). For optimization pur-
poses, samples collected from several subjects using various tape
brands were weighed and tested with an hK6 ELISA. Nichiban tape
yielded the highest levels of hK6 among all samples tested, which
indicated the lowest contamination of adhesive material after pu-
rification. The tape stripping was performed as follows: subjects
took a shower the night before and used no topical agents
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afterwards. The following afternoon, the tape was applied to the
skin surface of the subjects’ forearm and upper arm. As the
number of SC layers in the forearm is known to be consistent
regardless of age (Ya-Xian et al, 1999), we performed the stripping
at different places until around 2 mg of SC had been visibly ob-
tained. With this procedure, we assumed that a similar number of
SC layers had been removed in each case. The SC samples on the
tape were immediately stored at 201C until toluene treatment
was performed. When the tape was dipped in 10 mL of toluene, all
adhesive was dissolved and any attached SC was suspended.
After the insoluble tape backing was removed, the sample was
centrifuged at 1700  g for 15 min. The precipitate was washed
with 5 mL of toluene six times in order to remove any residual
adhesive. The amount of SC obtained was typically around 2 mg
regardless of subjects’ age and gender. After toluene treatment,
the purified samples were air dried, weighed, and kept at 201C
until immunofluorometric assays and enzymatic activity measure-
ments could be performed. As the stripping was less well tolerated
by children and seniors, the sample numbers for these subjects
were limited and data were not classified by gender.
For the immunofluorometric assays, 0.5 mg dry weight of the
SC samples were mixed with 20 mL of N,N-dimethylformamide,
480 mL of 0.1% Triton X-100, 350 mL of 0.2 M Tris-HCl buffer (pH
8.0), and 100 mL of H2O. The mixtures were incubated at 371C for 1
h on a shaker. Shorter or longer incubation times can cause lower
extraction efficiencies or degradation of hK, respectively. After in-
cubation, samples were then centrifuged at 1700  g for 10 min
and the supernatants retrieved. Fifty microliter aliquots were used
in each immunofluorometric assay for hK4, 6, 10, 13, and 14. For
hK5, 7, 8, and 11 assays, 10 mL aliquots were diluted with 40 mL of
the same mix solution, as described above. To test our extraction
efficiency, the SC samples were incubated in the extraction solu-
tion for 1 h and then centrifuged. The supernatants were collected
as the ‘‘first extraction.’’ Next, the insoluble SC material was re-
extracted as above. The supernatant from the second extraction
was then collected after centrifugation. The first and second ex-
tracts were assayed for kallikreins by ELISA and the results com-
pared. The ratio of major hK in the first versus second extract was
approximately 40:1 (97.5%). In the case of the minor hK, the con-
centration became undetectable in the second extract.
Immunoﬂuorometric assays for human tissue kallikreins With
the exception of mouse monoclonal FB6MA53 anti-hK11 antibody
(Ab), which was purchased (Fuso, Osaka, Japan); all other mono-
clonal and polyclonal anti-kallikrein Ab described in Table II were
developed in our laboratory. All ELISA assays displayed negligible
cross-reactivity with other kallikreins (data not shown).
Sandwich-type, non-competitive immunoassays (Dickson et al,
1995; Ferguson et al, 1996) were generally performed as follows
(more details are shown in Table II). White polystyrene microtiter
plates were coated with 100 mL per well (250 or 500 ng) of coating
Ab solution (50 mM Tris, pH 7.8) and incubated overnight at room
temperature. On the following day, the plates were washed three
times with the washing buffer (9 g per liter NaCl and 0.5 g per liter
Tween 20 in 10 mM Tris buffer, pH 7.4). Fifty microliters of assay
calibrators and undiluted or diluted samples were then pipetted
into each well, in duplicate, along with 50 mL of assay buffer (60 g
per liter bovine serum albumin (BSA), 50 mM Tris (pH 7.8), 0.5 g per
liter NaN3, 0.5 M KCl, 100 mg per liter goat IgG (Sigma, St Louis,
Missouri, USA), 20 mg per liter mouse IgG (Fortron, Morrisville,
North Carolina, USA), 1.0 g per liter bovine IgG (Sigma), and 0.5%
Tween 20, and incubated for 2 h with shaking at room temperature.
The plates were then washed with washing buffer six times. Sub-
sequently, 100 mL of the diluted anti-hK detection Ab (monoclonals
were biotinylated) in assay buffer were applied to each well and
incubated for 1 h with shaking at room temperature. The plates
were then washed six times. Finally, 100 mL of alkaline phospha-
tase (ALP)-conjugated goat anti-rabbit (Hþ L fragment-specific)
IgG antibody (Jackson ImmunoResearch, West Grove, Pennsylva-
nia) or streptavidin (SA)–ALP conjugate (Jackson ImmunoRe-
search), diluted in assay buffer or BSA (60 g per liter BSA, 50
mM Tris, pH 7.8, 0.5 g per liter NaN3) were added to each well and
incubated for 45 or 15 min, respectively. The plates were then
washed three times as described above. One hundred microliters
of 1 mM diflunisal phosphate in substrate buffer (0.1 M Tris (pH
9.1), 0.1 M NaCl, and 1 mM MgCl2) were added to each well and
incubated for 10 min. Finally, 100 mL of a developing solution con-
taining 1 M Tris base, 0.4 M NaOH, 2 mM Terbium (III) chloride
(TbCl3), and 3 mM EDTA was pipetted into each well and mixed for
1 min. The fluorescence was then measured with the Cyberfluor
615 time-resolved fluorometer (MDS Nordion, Kanata, ON, Cana-
da). The calibration and data reduction were performed automat-
ically as described elsewhere (Dickson et al, 1995; Ferguson et al,
1996).
Further details for each kallikrein ELISA immunoassay have
been published for hK4 (Obiezu et al, 2002), hK5 (Yousef et al,
2003b), hK6 (Diamandis et al, 2000), hK7 (Kishi et al, 2004), hK8
(Kishi et al, 2003), hK10 (Luo et al, 2001), hK11 (Diamandis et al,
2002), hK13 (Kapadia et al, 2003), and hK14 (Borgono et al, 2003).
Assay of trypsin- and chymotrypsin-like enzymatic activi-
ties The synthetic peptide substrate Boc-Phe-Ser-Arg-AMC
(7-amino-4-methyl-coumarin) (Peptide Institute, Osaka, Japan)
was used for the assay of trypsin-like activity, and MeO-Suc-Arg-
Pro-Tyr-pNA-HCl (3-carbomethoxypropionyl-L-arginyl-L-prolyl-L-
Tyrosine-p-nitroaniline hydrochloride) (Chromogenix, Milano, Italy)
was used for the assay of chymotrypsin-like activity. The reaction
mixtures consisted of 0.5 mg dry weight of SC, 10 mL of N,N-
dimethylformamide, 240 mL of 0.1% Triton X-100, 175 mL of 0.2 M
Tris-HCl buffer (pH 8.0), and 50 mL of either 1 mM trypsin-like ac-
tivity substrate or 4 mM of chymotrypsin-like activity substrate
(Komatsu et al, 2002). The mixtures were incubated at 371C for 1–4
h with shaking. Released AMC was measured using a fluorescence
spectrophotometer (FluoroScan Ascent FL, Labsystems, Helsinki,
Finland; excitation/emission¼ 355/460 nm), calibrated using refer-
ence standard AMC (Molecular Probes, Eugene, Oregon). Porcine
trypsin type II (Trypsin tablets, Sigma; molecular weight 23.8 kDa)
was used as a positive control. Released pNA by chymotrypsin-like
activity was measured spectrophotometrically at 405 nm (Wallac
Victor2 1420 Multilabel counter, Perkin Elmer, Boston, Massachu-
setts). All measurements were performed in triplicate.
Statistical analysis Differences in either the concentrations of
each kallikrein or enzyme activities between groups of subjects
were determined by either two-way or one-way ANOVA, respec-
tively. The reported p-values were adjusted by the Bonferroni
method to reflect multiple comparisons. These tests were per-
formed using GraphPad Prism 4, version 4.02 software (GraphPad
Software Inc.).
We would like to thank our volunteers for generously providing samples
and K. Hama, Y. Obata, and T. Toyama, for technical help.
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